Education
About Us
Working with TipRanks
Follow Us
Fresenius SE & Co (FSNUY)
OTHER OTC:FSNUY
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.21Last Year’s EPS
0.22Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 5.97%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted a strong start to 2025 with significant achievements in EPS growth, business momentum in Kabi and Helios, and strategic deleveraging. However, challenges such as the absence of energy relief in Germany, potential U.S. tariff impacts, and market challenges in China were noted.Company Guidance
In the Q1 2025 earnings call, Fresenius reported a strong start to the fiscal year, reaffirming its full-year guidance. Key metrics highlighted include a 7% organic top-line growth and 4% EBIT growth at constant currency, alongside a significant 12% increase in EPS due to improved capital deployment and portfolio optimization. Kabi achieved a notable EBIT margin of 16.8%, propelled by its growth vectors, particularly in biopharma, which is nearing its structural EBIT margin range of 16% to 18%. Helios also showed robust performance, with Helios Spain achieving a 13.1% EBIT margin, while Helios Germany continues to focus on process efficiencies. The company has tightened its leverage target to a corridor of 2.5 to 3.0 net debt over EBITDA, ending the first quarter within this range. Additionally, Fresenius highlighted the successful sale of Fresenius Medical Care shares, which contributed to its strategic flexibility and balance sheet strength.Strong Start to 2025
Fresenius reported a strong start to 2025 with excellent momentum across its businesses and reconfirmed its full-year guidance.
Double-Digit EPS Growth
The company achieved a double-digit EPS growth, reflecting efforts in turning around the company with a 12% increase in core EPS performance in the first quarter.
Kabi's Strong Performance
Kabi delivered strong top line growth driven by biopharma, with an EBIT margin increase to 16.8% and organic revenue growth of 6%.
Helios' Encouraging Start
Helios had an encouraging start to the year with organic revenue growth of 8% and Helios Spain achieving a 13.1% EBIT margin.
Deleveraging and Balance Sheet Strength
The company reduced its leverage to 3x net debt to EBITDA and aims to further strengthen the balance sheet with proceeds from the divestment of Fresenius Medical Care.
Biopharma Momentum
Biopharma showed significant momentum with 40% organic top line growth and profitability improvements.
FSNUY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FSNUY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $11.90 | $12.09 | +1.60% |
Feb 26, 2025 | $9.45 | $10.07 | +6.56% |
Nov 06, 2024 | $9.08 | $9.18 | +1.10% |
Jul 31, 2024 | $8.49 | $8.84 | +4.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fresenius SE & Co (FSNUY) report earnings?
Fresenius SE & Co (FSNUY) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Fresenius SE & Co (FSNUY) earnings time?
Fresenius SE & Co (FSNUY) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FSNUY EPS forecast?
FSNUY EPS forecast for the fiscal quarter 2025 (Q2) is 0.21.